GFM
TCRX icon

GF Fund Management’s TScan Therapeutics TCRX Stock Holding History

GF Fund Management’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,020
Closed -$1.86K – 694
2025
Q3 		$1.86K Sell
1,020
-198
-16% -$351 ﹤0.01% 625
2025
Q2 		$1.77K Hold
1,218
– – ﹤0.01% 649
2025
Q1 		$1.68K Buy
1,218
+187
+18% +$404 ﹤0.01% 654
2024
Q4 		$3.13K Buy
+1,031
New +$4.67K ﹤0.01% 629

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return

GF Fund Management's TCRX Position: Q4 2025 in Review

GF Fund Management sold out of TScan Therapeutics (TCRX) in Q4 2025, closing a stake of 1,020 shares — an estimated $1.86K sold.

GF Fund Management first reported a position in TCRX in Q4 2024 and held it in 4 quarters. The position peaked at $3.13K in Q4 2024. 61 funds tracked by Wall St. Rank hold TCRX as of Q4 2025.

  • GF Fund Management reported no remaining TScan Therapeutics position as of Q4 2025 after selling out during the quarter.
  • GF Fund Management sold 1,020 TScan Therapeutics shares in Q4 2025, an estimated $1.86K.
  • GF Fund Management first reported a position in TScan Therapeutics in Q4 2024 and held it in 4 quarters.
  • GF Fund Management's TScan Therapeutics position peaked at $3.13K in Q4 2024.
  • 61 funds tracked by Wall St. Rank held TScan Therapeutics as of Q4 2025.

Based on GF Fund Management's 13F filing for Q4 2025, filed 27 Jan 2026.